Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
Stopped slow accrual
Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Human Papillomavirus Positive
- Oropharyngeal Squamous Cell Carcinoma
- p16 Positive Neoplastic Cells Present
- Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
- BIOLOGICAL: Durvalumab
- PROCEDURE: Modified Radical Neck Dissection
- OTHER: Quality-of-Life Assessment
- OTHER: Questionnaire Administration
- RADIATION: Stereotactic Body Radiation Therapy
- PROCEDURE: Transoral Robotic Surgery
- BIOLOGICAL: Tremelimumab
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators